

***Plasmodium falciparum*, Strain NF54 (Patient Line E)**

Catalog No. MRA-1000

This reagent is the tangible property of the U.S. Government.

Product Description: The E line of NF54 stock parasites was amplified in a volunteer patient “E”, who participated in a clinical trial in 1995 at Walter Reed Army Institute of Research (WRAIR). The parent NF54 strain of *Plasmodium falciparum* (*P. falciparum*) was isolated from a patient living near an airport in the Netherlands, who had never left the country.

Lot¹: 70017917

Manufacturing Date: 07AUG2018

TEST	SPECIFICATIONS	RESULTS
Identification by Giemsa Stain Microscopy^{2,3}	Blood-stage parasites present	Blood-stage parasites present
Antimalarial Susceptibility Profile (<i>in vitro</i>)² Half-maximal Inhibitory Concentration (IC ₅₀) by SYBR green I [®] drug sensitivity assay ⁴ Chloroquine Artemisinin Quinine Cycloguanil Pyrimethamine Sulfadoxine	Report results Report results Report results Report results Report results Report results	7.7 ± 0.7 nM 13.2 ± 0.9 nM 53.6 ± 4.9 nM 22.7 ± 2.1 nM 64.9 ± 4.5 nM 319800 ± 14733 nM
Genotypic Analysis² Sequencing of Merozoite Surface Protein 2 (MSP2) gene (~ 740 base pairs)	≥ 99% sequence identity to <i>P. falciparum</i> , strain NF54 (GenBank: AMYQ01000292)	99.9% sequence identity to <i>P. falciparum</i> , strain NF54 (GenBank: AMYQ01000292) (Figure 1)
Functional Activity by PCR Amplification² MSP2 PCR amplicon analysis ⁵	~ 600 to 900 base pair amplicon	~ 900 base pair amplicon
Level of Parasitemia Pre-freeze ^{6,7} Ring-stage parasitemia Total parasitemia Post-freeze ^{2,8} Ring-stage parasitemia Total parasitemia	Report results ≥ 2% Report results ≥ 1%	2.65% 5.08% 2.81% 4.82%
Viability^{2,9}	Growth in infected red blood cells	Growth in infected red blood cells
Sterility (21-day incubation)² Harpo's HTYE broth ¹⁰ , 37°C and 26°C, aerobic Tryptic Soy broth, 37°C and 26°C, aerobic Sabouraud Dextrose broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep Blood agar, 37°C, aerobic Sheep Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic	No growth No growth No growth No growth No growth No growth No growth No growth	No growth No growth No growth No growth No growth No growth No growth No growth
Mycoplasma Contamination² DNA Detection by PCR	None detected	None detected

¹MRA-1000 was produced by cultivation of BEI Resources MR-MRA-1000 lot 58607195 in fresh human erythrocytes suspended in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 µg/mL hypoxanthine and 2.5 µg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N₂, 5%

- CO₂, 5% O₂) and monitored for parasitemia daily for 11 days. Every 2 to 3 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture as needed and monitored for hematocrit.
- ²Testing completed on viald post-freeze material.
- ³Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 4 days.
- ⁴A SYBR Green I[®] anti-malarial drug sensitivity assay in 96-well plates was used to determine IC₅₀ values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I[®]-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In *Methods in Malaria Research Sixth Edition*. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: <https://www.beiresources.org/Publications/MethodsInMalariaResearch.aspx>].
- ⁵Primer sequences and conditions for PCR are available upon request.
- ⁶Testing completed on bulk material prior to vialing and freezing.
- ⁷Parasitemia was determined after 11 days post infection by microscopic counts of Giemsa-stained blood smears.
- ⁸Post-freeze parasitemia was determined after 4 days post infection by microscopic counts of Giemsa-stained blood smears.
- ⁹Viability was confirmed by examination of infected erythrocytes for parasitemia at 4 days post infection.
- ¹⁰Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

Figure 1: MRA-1000 MSP2 Sequence

```
TATTATAAAT TTCTTTATTT TTGTTACCTT TAATATTTAAA AATGAAAAGTA AATATAGCAA CACATTCATA AACAAATGCTT
ATAATATGAG TATAAGGAGA AGTATGGCAG AAAGTAAGCC TTCTACTGGT GCTGGTGGTA GTGCTGGTGG TAGTGCTGGT
GGTAGTGCTG GTGGTAGTGC TGGTGGTAGT GCTGGTGGTA GTGCTGGTTC TGGTGATGGT AATGGTGCAG ATGCTGAGGG
AAGTTCAAGT ACTCCCCTA CTACCACAAC TACCAAAACT ACCACAATA CCACAATACT TAATGATGCA GAAGCATCTA
CCAGTACCTC TTCAGAAAAT CCAAATCATA AAAATGCCGA AACAAATCCA AAAGGTAAAG GAGAAGTTCA AGAACCAAAT
CAAGCAAATA AAGAACTCA AAATAACTCA AATGTTCAAC AAGACTCTCA AACTAAATCA AATGTTCCAC CCACTCAAGA
TGCAGACACT AAAAGTCTTA CTGCACAACC TGAACAAGCT GAAAATTCTG CTCCAACAGC CGAACAAAAT GAATCCCCCG
AATTACAATC TGCACCAGAG AATAAAGGTA CAGGACAACA TGGACATATG CATGGTTCTA GAAATAATCA TCCACAAAAT
ACTTCTGATA GTCAAAAAGA ATGTACCGAT GGTAACAAAG AAAACTGTGG AGCAGGCAAC ATCCCTCTTA AATAACTCTA
GTAATATTGC TTCAATAAAT AA
```

/Heather Couch/
Heather Couch

27 NOV 2018

Program Manager or designee, ATCC Federal Solutions

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

